After its latest pipeline clear-out, Merck KGaA is no longer pursuing any clinical-stage cancer candidates obtained through ...
LLY's shares fall 5% in a month amid pricing fears and obesity-drug rivalry, but booming Mounjaro and Zepbound sales and a deep pipeline keep growth hopes alive.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results